Premium
Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies
Author(s) -
Schöfer H.
Publication year - 2007
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2007.08274.x
Subject(s) - imiquimod , genital warts , dermatology , medicine , university hospital , family medicine , syphilis , human immunodeficiency virus (hiv)
Summary External genital and anal warts (acuminate condyloma) were the first medical indication the topical immune response modifier imiquimod was approved for in 1997. Since then, many placebo controlled randomized clinical trials have demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate for the treatment of different human papillomavirus infections and tumours. Treatment modalities for genital warts (5% cream, three times weekly, minimum duration 4 weeks, control of side‐effects) have been optimized and assured by further clinical trials and meta‐analyses. For a few years clinical studies focussed on the long‐term efficacy of the immunomodulatory therapy (sustained clearance from warts) and most recent studies compared the efficacy of ablative, destructive and imiquimod monotherapy as well as combination therapies.